企業概要
Agilon Health, Inc. operates within the healthcare sector, specifically focusing on the medical care facilities industry, where it delivers essential primary care services to senior populations across the United States through a network of community-based physicians. The firm utilizes a subscription-like per-member-per-month model to manage the comprehensive healthcare needs of its patient base, distinguishing its operational approach from traditional fee-for-service arrangements. As of the latest available data, the company holds a market capitalization of $329.46 million and generates annual revenue of $5.93 billion, supported by a workforce of 856 employees. These financial figures indicate that while the company operates with a substantial revenue base, its market valuation reflects a smaller capitalization relative to its top-line performance, suggesting a specific positioning within the specialized senior care infrastructure rather than a broad commercial healthcare conglomerate.
財務健全性
The company reported revenue of $5.93 billion for the trailing twelve months, yet recorded a net income loss of $405,347,008 and an EBITDA loss of $406,182,016, revealing a significant gap between top-line generation and profitability that points to a highly leveraged cost structure or substantial investment in infrastructure. Free cash flow stood at -$81,226,128, which indicates a current lack of financial flexibility for capital expenditures without external financing, as operational cash outflows exceed cash inflows from core activities. The gross margin is negative at -2.7%, while the operating margin sits at -10.0% and the profit margin at -6.6%, collectively signaling that the company is currently operating at a loss across all major profitability metrics, likely due to high fixed costs associated with managing elderly care services. On the balance sheet, the company holds $285.14 million in cash against $36.81 million in debt, resulting in a debt-to-equity ratio of 29.05, which suggests a leveraged position despite the absolute debt amount being low relative to cash reserves. The current ratio is 1.02, indicating that the company's current assets barely exceed its current liabilities, implying tight short-term liquidity management with limited buffer for unexpected obligations. Furthermore, the return on equity is -135.6% and the return on assets is -17.5%, metrics that reveal that management is currently unable to generate positive returns on the capital invested or the assets employed, reflecting the challenges inherent in the expansion or restructuring phase of the business.
バリュエーション評価
The valuation metrics present a complex picture, with a forward P/E ratio of -5.42 and a trailing P/E ratio marked as N/A, implying that the company is currently unprofitable and traditional earnings-based valuation models are not applicable in the conventional sense. The price-to-book ratio stands at 2.60, which indicates that the market values the company at a significant premium over its tangible book value, a phenomenon often seen in firms with intangible assets or high growth expectations despite current losses. Alternative valuation measures include a price-to-sales ratio of 0.06 and an EV/EBITDA of -0.20, suggesting that the market prices the stock based on revenue multiples given the lack of earnings, while the negative EV/EBITDA reinforces the company's current negative earnings power. Regarding trading ranges, the 52-week high is $152.00 and the 52-week low is $7.48; without a specific current price provided in the facts, the exact percentage deviation cannot be calculated, but the wide spread highlights extreme price volatility over the last year. The beta value is 0.33, which signifies that the stock's price volatility is substantially lower than that of the broader market, behaving more like a defensive asset despite its financial losses and high beta typically associated with high volatility.
Growth & Income
Revenue growth year-over-year is recorded at 3.1%, whereas earnings growth is N/A due to the company's lack of profitability, indicating that top-line expansion is occurring without immediate translation into bottom-line gains. As a non-dividend payer, the company does not distribute a dividend yield or has a payout ratio of 0.0%, meaning that any generated earnings, if they were positive, would theoretically be reinvested into operations rather than distributed to shareholders, though currently, the firm consumes cash for operations. The overall growth and income profile characterizes Agilon Health as a high-revenue, loss-making entity that prioritizes market expansion and service delivery over immediate profitability or income distribution to investors.